SCHEMBL3377808

SCHEMBL3377808

c1nc(-c2cnn([C]3CCCC3)c2)c2cc[nH]c2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 19/20 0.50
JAK1 P23458 12/20 0.50
JAK3 P52333 7/20 0.50
HDAC6 Q9UBN7 7/20 0.50
TYK2 P29597 4/20 0.50
RET P07949 3/20 0.50
ROCK1 Q13464 3/20 0.50
DAPK3 O43293 2/20 0.50
PAK4 O96013 2/20 0.50
ABL1 P00519 2/20 0.50
LTK P29376 2/20 0.50
CSNK1A1 P48729 2/20 0.50
CLK2 P49760 2/20 0.50
TNK2 Q07912 2/20 0.50
DYRK1A Q13627 2/20 0.50
IKBKE Q14164 2/20 0.50
NTRK3 Q16288 2/20 0.50
NTRK2 Q16620 2/20 0.50
LRRK2 Q5S007 2/20 0.50
TAOK1 Q7L7X3 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3376129 0.99 JAK2 (0.49) JAK2JAK1JAK3HDAC6TYK2
Acetonitrile SCHEMBL18036542 0.93 JAK2 (0.52) JAK2JAK1JAK3HDAC6TYK2
SCHEMBL2358804 0.80 JAK2 (0.49) JAK2JAK1JAK3HDAC6TYK2
SCHEMBL13286408 0.80 AURKA (0.62) JAK2JAK1JAK3HDAC6TYK2
SCHEMBL30589328 0.80 AURKA (0.62) JAK2JAK1JAK3HDAC6TYK2
SCHEMBL3375416 0.80 GRM4 (0.67) JAK2JAK1JAK3TYK2RET
SCHEMBL3378527 0.79 JAK1 (0.60) JAK2JAK1JAK3HDAC6TYK2
SCHEMBL3374026 0.79 JAK2 (0.51) JAK2JAK1JAK3HDAC6TYK2
SCHEMBL6126705 0.79 HTR2C (0.44) JAK2JAK1JAK3HDAC6TYK2
SCHEMBL3376608 0.78 JAK2 (0.49) JAK2JAK1JAK3TYK2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11957931-B2 Compositions and methods for treating vitiligo YALE UNIVERSITY (US) 2024-04-16 US disclosed
US-20200069965-A1 Compositions and Methods for Treating Vitiligo UNIV YALE (US) 2020-03-05 US disclosed
CN-105541847-A Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile INCYTE CORP 2016-05-04 CN disclosed
CN-102596960-B Hydroxy, keto, and glucuronide derivatives of 3- (4- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile INCYTE CORP. (US) 2016-01-20 CN disclosed
CN-101815717-B Metabolites of the JANUS kinase inhibitor -3- (4- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile INCYTE CORP 2014-06-25 CN disclosed
WO-2013173506-A2 METHOD OF TREATING MUSCULAR DEGRADATION RIGEL PHARMACEUTICALS, INC. (US) 2013-11-21 WO disclosed
CN-102596960-A Hydroxy, keto, and glucuronide derivatives of 3- (4- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile INCYTE CORP 2012-07-18 CN disclosed
CN-101815717-A Metabolites of the JANUS kinase inhibitor -3- (4- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile INCYTE CORP 2010-08-25 CN disclosed
WO-2010039939-A1 JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES INCYTE CORPORATION (US) 2010-04-08 WO disclosed